Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander‐Tetri(Saint Louis University), Edward Doo(National Institutes of Health), David E. Kleiner(National Institutes of Health), Norah A. Terrault(University of Southern California), Anna Mae Diehl(Duke Medical Center), Joel E. Lavine(Columbia University), Rohit Loomba(University of California San Diego), Mark L. Van Natta(Johns Hopkins University), Arthur J. McCullough(Cleveland Clinic), Jeanne M. Clark(Johns Hopkins University), Arun J. Sanyal(Virginia Commonwealth University), Elizabeth M. Brunt(Washington University in St. Louis), Bilal Hameed(University of California, San Francisco), Kris V. Kowdley(Liver Institute Northwest), James Tonascia(Johns Hopkins University), Srinivasan Dasarathy(Cleveland Clinic), Naga Chalasani(Indiana University – Purdue University Indianapolis), Manal F. Abdelmalek(Mayo Clinic)
Cited by 2,182
Related Papers
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
|Hepatology|2017|7.2k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k